Inversago Pharma

Leading the Way
in Peripheral CB1
Blockade

We Leverage the
Full Potential of
Peripherally-acting
CB1 Inverse Agonists

About Inversago Pharma

Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D) Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) and other conditions.

The Peripheral CB1 Company

Targeting metabolic diseases in need of better adapted treatment options

Inversago has the know-how, technology and clinical expertise to develop safe and potent first-in-class inverse agonists of peripheral CB1 receptors to address a broad range of medical indications (conditions related to obesity such as diabetes (diabetic kidney disease (DKD), type 1 and type 2 diabetes and hypertriglyceridemia (HTG))), liver diseases (NASH) or fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD) and other conditions.

INV-202, our lead program targeting metabolic disorders, is a next generation, peripherally-acting CB1 inverse agonist in clinical development. Our other candidate molecules targeting the peripheral CB1 pathway have also shown activity in several preclinical models.

Learn More

Indications

Inversago Pharma is focused on one objective: the development of inhibitors targeting the peripheral CB1 receptors.

Clinical and scientific data clearly suggest that the peripheral CB1 pathway is implicated in the pathophysiology of a majority of metabolic and fibrotic diseases.

The company’s development programs aim to provide novel therapies for the treatment of a series of metabolic conditions, such as diabetic kidney disease, type 1 and type 2 diabetes, non-alcoholic steatohepatitis, hypertriglyceridemia, and fibrotic indications such as progressive fibrosis – interstitial lung disease.